Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells



Airway inflammation is a key feature of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroids (ICS) remain the main treatment for airway inflammation. Studies have noted the increased efficacy of ICS and long-acting beta 2 agonist (LABA) combination therapy in controlling exacerbations and improving airway inflammation than either monotherapy. Further studies have suggested that LABAs may have inherent anti-inflammatory potential, but this has not been well-studied.


We hypothesize that the LABA olodaterol can inhibit airway inflammation resulting from exposure to respiratory syncytial virus (RSV) via its binding receptor, the β2-adrenergic receptor.


Human bronchial epithelial brushing from patients with and without COPD were cultured into air–liquid interface (ALI) cultures and treated with or without olodaterol and RSV infection to examine the effect on markers of inflammation including interleukin-8 (IL-8) and mucus secretion. The cell line NCI-H292 was utilized for gene silencing of the β2-adrenergic receptor via siRNA as well as receptor blocking via ICI 118,551 and butaxamine.


At baseline, COPD-ALIs produced greater amounts of IL-8 than control ALIs. Olodaterol reduced RSV-mediated IL-8 secretion in both COPD and control ALIs and also significantly reduced Muc5AC staining in COPD-ALIs infected with RSV. A non-significant reduction was seen in control ALIs. Gene silencing of the β2-adrenergic receptor in NCI-H292 negated the ability of olodaterol to inhibit IL-8 secretion from both RSV infection and lipopolysaccharide stimulus, as did blocking of the receptor with ICI 118,551 and butaxamine.


Olodaterol exhibits inherent anti-inflammatory properties on the airway epithelium, in addition to its bronchodilation properties, that is mediated through the β2-adrenergic receptor and independent of ICS usage.


Chronic obstructive pulmonary disease (COPD) is a highly prevalent condition that is characterized by persistent airflow limitation and is a major cause of morbidity and mortality worldwide [1, 2]. In addition to parenchymal destruction, chronic inflammation can lead to airway remodeling and narrowing, which contributes to the characteristic reduction in airflow and symptoms of cough, shortness of breath and excess sputum production present in COPD [3]. The clinical course is frequently punctuated by periods of acute symptom worsening, which are called exacerbations. These exacerbations are responsible for a large number of hospitalizations each year that exact heavy economic and societal burdens on the healthcare system [4]. The most common triggers for acute exacerbations of COPD are viral respiratory tract infections, which can also initiate chronic airway inflammation by inducing innate immune responses that activate pro-inflammatory mediators [5,6,7]. One of the more common pathogens is respiratory syncytial virus (RSV), which directly infects the airway epithelium [1, 5, 7].

Popular symptomatic management for patients with COPD include bronchodilators such as the long-acting β2-agonists (LABAs) which target airway epithelia and smooth muscle cells [2, 8, 9]. First approved in 2013, olodaterol (Striverdi “Respimat”) is a novel inhaled ultra-LABA with over 24 h of bronchodilatory effect [2, 10,11,12]. It is a potent and selective β2-adrenergic receptor (β2AR) agonist with a rapid onset of action [8, 9, 13]. By forming a stable complex with the β2ARs located in airway smooth muscles cells, olodaterol not only relaxes airway smooth muscles by stimulating adenylyl cyclase to upregulate cyclic AMP production, but also maintains broncho-protection for 24 h and therefore enables its once-daily dosing regimen [8, 14, 15]. Usage of LABAs (such as salmeterol) has been shown to decrease the risk of exacerbations in COPD patients by up to 20% compared to a placebo [16], but this is not well understood. It has been suggested that this may be due to synergy with inhaled corticosteroids, which result in an amplified anti-inflammatory effect [17], but a meta-analysis showed that LABAs were able to inhibit exacerbations in the absence of ICS as well [18]. The airway epithelium plays a key role in initiaing immune responses [19]. Therefore, we hypothesize that LABAs have their own intrinsic anti-inflammatory effects when applied to the airways of COPD patients via the airway epithelium.

Materials and methods

Reagents and supplies

Olodaterol hydrochloride [BI 1744 Cl] was provided by Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. Interleukin (IL-8) ELISA kit [Cat# CHC1303] was purchased from Life Technologies (Carlsbad, CA, USA). Anti-Muc5AC antibody [Cat# ab24071] for immunohistochemistry was purchased from Abcam (Cambridge, United Kingdom). ICI 118,551 hydrochloride [Cat# I127-5MG] was purchased from Sigma Aldrich (St. Louis, MO, US). Butaxamine hydrochloride [B1385-50MG] was also purchased from Sigma Aldrich.

Respiratory syncytial virus (RSV) preparation

Human Long strain, type A RSV (American Type Culture Collection (ATCC), Rockville, MD, USA) was propagated on Hep-2 (ATCC) cell monolayers as previously described [20]. The culture medium consisted of Dulbecco’s Minimum Eagle Medium (DMEM) containing heat inactivated 10% fetal bovine serum (FBS), 100 U/mL penicillin/streptomycin, non-essential amino acids and sodium pyruvate was incubated at 37 °C in a 5% CO2 incubator. After 4 days of culture, the condition media containing free virus was harvested and centrifuged at 10,000×g for 10 min at 4 °C to remove cellular debris. The clear supernatants were then pooled and concentrated by ultrafiltration through a 100 kDa cut-off membrane [Cat# UFC910008] from Millipore (Burlington, MA, USA) according to the manufacturer’s instructions. RSV infection was performed at multiplicity of infection 1 (MOI1) for 90 min as per previously published protocols [21]. Following viral infection, cultures were washed with PBS to remove unbound virus and exposed to air for 16 h.

Cell culture

A total of 10 subjects (5 COPD and 5 controls) were grouped based on spirometry results according to recommendations by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [22] whereby subjects with normal lung function were considered controls. Of the five subjects in the COPD cohort and the five subjects in the non-COPD cohort, one was a non-smoker, two were former smokers and two were current smokers. The patient demographics information is shown in Table 1. Three out of the five COPD subjects were using pulmonary medications (LAMA/SABA/Prednisone, LABA/SABA, budesonide). Non-COPD subjects were not using any pulmonary medication. All subjects underwent bronchoscopy for a variety of different clinical indications including evaluation of lung nodules/masses and chronic cough. Prior to bronchoscopy, all subjects underwent thoracic computed tomography (CT) as per protocol. Using cytology brushes [Cat# 4206] from Primed Canada, human primary bronchial epithelial cells (BEC) were collected in small airways (< 2 mm in diameter), generally in the right upper or left upper lobes, far away from any nodules or masses as noted on chest CTs (usually in the contralateral lung). All experiments in this study were approved by the Research Ethics Board of University of British Columbia/Providence Healthcare (REB# H11-02713 and REB# H15-01778). Patient-derived bronchial epithelial cells (BECs) were cultured in Pneumacult-Ex medium [Cat# 05008] from STEMCELL Technologies (Vancouver, BC, Canada). Cells were seeded at 80,000 per well in a 24-well plate and differentiation was induced once the cells reached 100% confluency.

Table 1 BEC subject demographics information

NCI-H292 lung epithelial cells were purchased from the ATCC and grown in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% heat-inactivated FBS. The NCI-H292 cells were cultured at 37 °C in a 5% CO2 humidified incubator. The media was changed three times per week and the cells were passaged once they reached 90–100% confluence. Cells were used experimentally between passages 75–90.

ALI cell culture

Air–liquid interface (ALI) cultures were grown on 24-well Corning cell culture inserts [Cat# 3470] using Pneumacult-ALI media [Cat# 0051] from STEMCELL Technologies and protocol as previously detailed [23]. Cultures were maintained as ALIs for 21–28 days until pseudostratification of the epithelium was visualized via microscopy to contain various epithelial cell types. Medium replaced 3 times per week and the apical surface rinsed with warm phosphate buffered saline (PBS) weekly to study the effects of olodaterol treatment on the apical surface with and without RSV infections.

10 µM olodaterol treatment was administered on the apical side for 8 h, followed by aspiration of the olodaterol-containing media and exposing the cultures to air for 16 h. This pre-treatment procedure was repeated for 3 days for a total of 24 h drug exposure, to better mimic the in vivo patient regiment. ALI cultures were not exposed to olodaterol treatment on the apical side for 24 continuous hours as this would lead to de-differentiation of the pseudostratified epithelium.

Immunohistochemical (IHC) analysis

ALI cultures with or without olodaterol and RSV treatments were processed as formalin-fixed-paraffin-embedded (FFPE) blocks, and cut into 4 μm sections. Sections were de-paraffinized in CitriSolv (Fisher Scientific, Toronto, ON, 22-143-975) and rehydrated. Expression level of mucin 5AC (Muc5AC) was detected via a Leica autostainer at 1:1000 primary anti-Muc5AC antibody dilution (AB24071, AbCam, Cambridge, MA, USA) and using the Bond Polymer Refine Red Detection kit on the Leica Bond Autostainer according to the manufacturer’s protocol.

Production of RSV viral particles in infected ALI cultures were also quantified. ALI sections were de-waxed, rehydrated, and subjected to heat-induced antigen retrieval in citrate buffer (pH 6.0, Invitrogen) for 22 min. All sections were blocked in universal protein block (Dako, Burlington, ON, Canada) at room temperature for 30 min before incubating with a 1:100 dilution of an RSV-specific antibody (NCL-RSV3, NovoCastra Labs), in Tris-buffered saline (TBS) overnight at 4 °C. The biotin-free MACH4 AP-Polymer Detection kit containing alkaline phosphatase (M4U536, Biocare Medical, Markham, ON) was then used to detect proteins of interest following manufacturer’s protocols with Warp Red Chromogen (WR806, Biocare Medical) as the substrate.

Negative controls were performed using a matched isotype antibody. Hematoxylin was used for counter-staining of the nuclei of all IHC. Colour segmentation via ImagePro Plus (Media Cybernetics, Silver Spring, MD, USA) was performed for quantification; the area of positivity was normalized to the total epithelial surface.

Olodaterol and LPS treatment in NCI-H292 cells

NCI-H292 cells were incubated with complete media containing olodaterol for 8 h. Following pre-treatment with olodaterol, LPS was added directly into the media to a final concentration of 2 µg/mL and the culture was allowed to incubate overnight at 37 °C for 16 h before the cell-free supernatant was collected.

siRNA transfections with olodaterol and RSV infection or lipopolysaccharide (LPS) treatment

Specific siRNAs targeting the β2AR mRNA transcript (Silencer Select s1121, s1122, s1223, s531994), scrambled non-targeting siRNA (Silencer Select 4390844) and GAPDH-targeting siRNA (Silencer Select 4390849) were purchased from Life Technologies. The β2AR siRNAs were combined in equal proportions to create a custom pool. All transfections were performed using lipofectamine RNAiMax (Life Technologies) according to the manufacturer’s instructions. Cells were plated in 24-well plates (CORNING, NY, USA) at 60,000 cells per well. Two days later, the cells were transfected with siRNA at 10 nM and incubated with the transfection complex for 24 h, after which the media was replaced with fresh complete media. After 48 h, media in the LABA treatment groups were replaced with complete media containing 10 µM olodaterol and allowed to incubate for 8 h. At 56 h, LPS was added to achieve a final concentration of 2 µg/mL and then incubated overnight. Alternatively for RSV infection, at 56 h media from all wells were removed and saved. Fresh complete media or RSV-containing media at MOI1 was added and allowed to incubate with the cells in a 37 °C humidified incubator for 90 min with hand shaking every 20 min to disperse the virus. After 90 min, cells were washed with PBS and aspirated before the original media was returned and the cultures allowed to incubate overnight. At 72 h, media and cell lysates were collected and centrifuged at 6000×g for 5 min to remove cellular debris. Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany).

Blocking of β2AR with ICI 118,551 and butaxamine

Blocking of the β2AR in NCI-H292 cells was performed using the β2AR-selective antagonists ICI 118,551 and butaxamine. ICI 118,551 was utilized at a final concentration of 30 nM and butaxamine was utilized at a final concentration 100 nM. Cells were incubated in complete media containing the respective antagonist for 1 h prior to other treatments.

Reverse cDNA synthesis and real-time quantitative polymerase chain reaction

cDNA was synthesized from total RNA isolates using the iScript cDNA Synthesis Kit (BioRad Laboratories, Hercules, CA, USA) and quantitative real-time PCR was performed using iTaq Universal Sybr Green Supermix (BioRad Laboratories). Subsequent data were normalized to the housekeeping gene hypoxanthine–guanine phosphoribosyltransferase (HPRT). Glycerol-3-phosphate dehydrogenase (GAPDH) was used to confirm the efficacy of the knockdown. Custom DNA primers targeting β2AR, GAPDH and HPRT cDNA transcripts were designed via PrimerBlast based on the sequence obtained from GeneBank (NM_000024.6) and are as follows: β2AR forward: 5′-ATGGGCACTTTCACCCTCTG-3′; β2AR reverse: 5′-GCTCCGGCAGTAGATAAG-GG-3′; GAPDH forward: 5′-AAGAAGGTGGTGAAGCA-GGC-3′; GAPDH reverse: 5′-CGTCAAAGGTGGAGGAGTGG-3′; HPRT forward: 5′-TGACACTGGCAAAACAATGCA-3′; HPRT reverse: 5′-GGTCCTTTTCACCAGCAAGCT-3′. Knockdown efficiency of the target genes were analyzed via the ddCt method.

Enzyme-linked immunosorbent (ELISA) assay

Concentrations of IL-8 in supernatants collected from primary ALI cultures and NCI-H292 cells were measured by ELISA as per manufacturer’s instructions.

Statistical analysis and data presentation

Results were analyzed using GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA, USA). Graphical values are represented as the mean ± standard error of mean. Two-tailed unpaired Student t-tests were used to compare the means between two groups while ANOVA with Bonferroni correction was used for multiple group comparisons.

Where possible, data generated via primary ALI cultures were normalized to internal experiment controls to maintain consistency across experiments. This is a result of primary cells having inherent genetic variability due to being sourced from different subjects. Hence, data are presented as “fold change” in place of absolute values. NCI-H292-generated data was not normalized as cell lines lack the heterogeneity of primary cultures.


BECs from COPD and control subjects were cultured and differentiated into ALI cultures to evaluate the effects of olodaterol on the integrity and function of airway epithelial cells. Olodaterol exposure and RSV infections were performed from the apical surface to mimic in vivo drug delivery and viral infections. IL-8, a cytokine that facilitates neutrophil chemotaxis, was chosen as our surrogate marker of inflammation due to the important role it plays in COPD pathogenesis [24]. Similarly, Muc5AC was examined as it is also a specific marker of inflammation in COPD [25].

Initial experiments determined that the chosen concentration for our study, 10 µM olodaterol, did not elicit significant inflammatory or cytotoxic effects in our culture (Additional file 1: Figure S1, S2).

COPD-ALI cultures release higher IL-8 at baseline

Cell-free supernatants collected from the basal compartments of both COPD and control ALI cultures were assayed for IL-8, a chemoattractant for neutrophils that has been implicated in COPD pathogenesis. As shown in Fig. 1, constitutive IL-8 expression was four-time higher in COPD-ALI cultures versus controls (p = 0.008).

Fig. 1

Basal concentrations of IL-8 are higher in ALI cells of COPD versus control subjects. At baseline, COPD-ALIs produced four times greater concentrations of IL-8 than control ALIs (**p < 0.01). n = 3. Data was analyzed via two-tailed unpaired Student t-test

Mucus production in ALI cultures via Muc5AC staining

Muc5AC is a key component of airway mucus. Staining was performed on ALIs as shown in Fig. 2a. Expression of Muc5AC was higher in ALIs treated with RSV alone compared to the untreated condition in both COPD-ALIs (Fig. 2c, p < 0.01) and control ALIs (Fig. 2b, non-significant increase). In COPD-ALIs, olodaterol-treated cells demonstrated a significant reduction in RSV-mediated Muc5AC expression compared to RSV-only cells (Fig. 2c, p < 0.01). A non-significant difference was seen in non-COPD ALI cultures, likely because the COPD ALIs are already at a heightened inflammatory state and thus primed to secrete more mucins at baseline. As such, the margin of change as facilitated by olodaterol is greater and more visible in the COPD ALIs than the control ALIs.

Fig. 2

The effect of olodaterol on Muc5AC expression with and without RSV infection. Mucus production was quantified by Muc5AC staining to visualize mucins. a Representative image of Muc5AC staining. b No significant change in Muc5AC expression with or without olodaterol and RSV treatment in control-ALIs. n = 4. c RSV infection significantly increased Muc5AC expression compared to the control (**p < 0.01) in COPD-ALIs. Additionally, olodaterol (OLO + RSV) significantly decreased RSV-mediated Muc5AC expression (**p < 0.01). Olodaterol concentration used was 10 µM. n = 3. Data was analyzed via one-way ANOVA with Bonferroni correction

Olodaterol inhibited RSV-induced inflammation

In both COPD and control ALI cultures, olodaterol treatment under control settings led to a slight reduction in baseline IL-8 secretion in the basal compartment compared to the untreated cultures (Fig. 3a, b), although the results were not statistically significant. This may indicate a propensity for olodaterol to inhibit baseline levels of inflammation independent of an inflammatory stimulus. Addition of olodaterol with RSV infection resulted in a significant 30% reduction in IL-8 fold change compared to RSV infection alone in the COPD-ALI (p < 0.01, Fig. 3a) and the control cultures (p < 0.05, Fig. 3b).

Fig. 3

The effect of olodaterol on IL-8 secretion in ALI-cultures. a In control ALIs, olodaterol (OLO)-treated cultures demonstrated a significant reduction in RSV-induced IL-8 secretion compared to RSV alone (*p < 0.05). n = 4. b COPD-ALI cultures showed a significant decrease in RSV-mediated IL-8 secretion when pre-treated with olodaterol (OLO + RSV) compared to RSV infection alone (**p < 0.01). Olodaterol concentration used was 10 µM. n = 4. Data was analyzed via one-way ANOVA with Bonferroni correction

Use of olodaterol exhibited a notable effect on the degree of viral infection as shown through immunohistochemical staining. A representative image of RSV staining is shown in Fig. 4a. Quantification analysis showed a significant reduction of RSV-positive cells in olodaterol-treated and RSV-infected ALIs compared to RSV alone for both COPD-ALI and control ALI cultures (p < 0.05, Fig. 4b, c). Olodaterol treatment appeared to reduce RSV infection in both COPD-ALI and control ALI.

Fig. 4

The effect of olodaterol on RSV infections. RSV staining was used to quantify RSV particles. a Representative image of RSV staining. b Control ALIs showed significantly decreased RSV staining with olodaterol treatment (OLO + RSV) compared to RSV-only infection (*p < 0.05). n = 3. c COPD-ALIs also showed significantly decreased RSV staining with olodaterol treatment (**p < 0.01). Olodaterol concentration used was 10 µM. n = 3. Data was analyzed via two-tailed unpaired Student t-test

β2AR is required for the inhibition of IL-8 secretion by olodaterol

NCI-H292, a lung epithelial cancerous cell line, was selected for investigation of the cellular mechanism behind olodaterol’s anti-inflammatory effect.

A dose response experiment, utilizing NCI-H292 stimulated with LPS at increasing log concentrations of olodaterol, was performed and the corresponding effect on IL-8 secretion was measured. As shown in Fig. 5, there is a clear pattern of increasing IL-8 inhibition with increasing olodaterol dosage. All tested olodaterol concentrations were able to significantly inhibit LPS-mediated IL-8 secretion in a dose-dependent manner. Olodaterol at a concentration of 10 µM elicited the greatest inhibition.

Fig. 5

Olodaterol dose response in NCI-H292 on LPS-mediated IL-8 secretion. NCI-H292 cells were treated with 2 µg/mL of LPS and increasing log doses of olodaterol (0.01, 0.1, 1 and 10 µM). Olodaterol concentrations of 0.01 µM, 0.1 µM, 1 µM and 10 µM all significantly inhibited IL-8 secretion compared to the LPS-only treatment (***p < 0.001, ****p < 0.0001, ****p < 0.0001 and ****p < 0.0001, respectively). n = 6. Data was analyzed via one-way ANOVA with Bonferroni correction

To determine whether the anti-inflammatory effect observed in the ALI cultures were mediated by the β2AR, siRNAs targeting the receptor were used to elicit gene silencing to approximately 80% inhibition of the mRNA in the NCI-H292 cell line (Additional file 1: Figure S3). Both RSV and LPS was used as the inflammatory stimulus in order to investigate the effect of different stimuli on olodaterol’s inhibition of IL-8. LPS has been used previously to investigate the anti-inflammatory effect of β2-agonists in the airway cell cultures [26, 27]. To examine the role of the β2AR in the anti-inflammatory effect of olodaterol, IL-8 secretion was measured. In RSV-infected cells, the inflammatory stimuli generated high amounts of IL-8 in non-transfected and scrambled siRNA transfected conditions while treatment with 10 µM olodaterol significantly attenuated these changes (Fig. 6a, p < 0.01 and p < 0.0001, respectively). The same result was seen with LPS stimulation (Fig. 6b, p < 0.001 and p < 0.001). However, when cells were transfected with siRNA targeting β2AR, olodaterol treatment failed to significantly inhibit IL-8 secretion resulting from RSV infection and LPS stimulation, indicating that β2AR is required for the inhibition of IL-8 by olodaterol. Furthermore, the results also indicate that the effects of olodaterol are not stimuli dependent.

Fig. 6

The effect of β2AR gene silencing on IL-8 secretion induced by RSV and LPS. a In non-transfected and scrambled siRNA-transfected cells, olodaterol inhibited RSV-mediated IL-8 secretion (OLO + RSV, **p < 0.01 and ****p < 0.0001 respectively) but not in β2AR siRNA-transfected cells. b Olodaterol attenuated LPS-mediated IL-8 secretion in non-transfected (OLO + LPS, ***p < 0.001) and scrambled siRNA-transfected cells (OLO + LPS, ***p < 0.001) but not in β2AR siRNA-transfected cells. n = 3. In both (a) and (b), β2AR siRNA negated olodaterol-mediated reduction of LPS-induced IL-8 secretion. Olodaterol concentration used was 10 µM. n = 3. Data was analyzed via two-way ANOVA with Bonferroni correction

To further support the concept that olodaterol’s anti-inflammatory effect is mediated via β2AR, we treated NCI-H292 cells with LPS and olodaterol in the presence of ICI 118,551 and butaxamine, both of which are β2AR-selective antagonists. Although we used 10 µM in the previous experiments, this dose was “supramaximal” and as such, the compound could not be fully antagonized in receptor blocking studies. Thus, to determine the optimal dose of olodaterol required for this experiment, we conducted a dose–reponse study in which we determined that 0.01 µM olodaterol was the lowest tested concentration that was effective in inhibiting IL-8 secretion. As shown in Fig. 7a, when cells were treated with LPS and 0.01 µM olodaterol, IL-8 secretion was decreased compared to LPS-only treatment (p < 0.01). However, when cells were treated with ICI 118,551 prior to the addition of olodaterol and LPS, the effect was no longer observed. Similarly in Fig. 7b, when the experiment was repeated with butaxamine, olodaterol was unable to suppress LPS-mediated IL-8 secretion.

Fig. 7

The effect of the β2AR antagonists ICI 118,551 and butaxamine on olodaterol inhibition of IL-8 secretion. NCI-H292 cells were treated with 2 µg/mL LPS with and without 0.01 µM olodaterol. To antagonize β2AR, cells were pre-treated with 30 nM of ICI 118,551 or 100 nM of butaxamine for 1 h, followed by addition of 0.01 µM olodaterol for 8 h and 2 µg/mL LPS overnight for a total of 24 h. a Olodaterol significantly inhibited LPS-mediated IL-8 secretion (**p < 0.01) but not in the presence of 30 nM of ICI 118,551. b Olodaterol also inhibited LPS-mediated IL-8 secretion (*p < 0.05) but not in the presence of 100 nM of butaxamine. n = 6. Data was analyzed via one-way ANOVA with Bonferroni correction


The most important and novel finding of our study was that olodaterol, an ultra-LABA, which is commonly used in COPD for bronchodilation, has significant anti-inflammatory effects in the airways of COPD patients. We showed that olodaterol was able to suppress inflammation related to RSV, a common respiratory pathogen that leads to COPD exacerbations, including suppression of IL-8 and airway mucin production/secretion and RSV viral particle production. We also showed that this anti-inflammatory effect was mediated through the β2-adrenergic receptor, the classic receptor for LABAs, as demonstrated through both siRNA gene silencing and receptor blocking experiments.

Some previously published literature have offered evidence that β2-adrenergic receptor agonists may have additional anti-inflammatory properties. This has been demonstrated previously with the SABA salbutamol, which was shown to inhibit p38 MAPK phosphorylation [28]. However, in regards to LABAs, they were first proposed to be anti-inflammatory based on the increased effectiveness of LABA/ICS combination therapy to attenuate airway inflammation compared to ICS monotherapy [29]. A popular theory was that it enhanced the anti-inflammatory effects of ICS by facilitating translocation of the glucocorticoid receptors into the nucleus [17]. However, a more recent study examining the molecular mechanisms of LABA/ICS treatment refuted this concept [30]. Several groups have noted that LABAs on their own (in the absence of glucocorticoids) demonstrate anti-inflammatory effects by inducing anti-inflammatory gene expression [30,31,32]. Consistent with these observations, in animal models, olodaterol has been shown to inhibit the recruitment of neutrophils to the lungs and the secretion of inflammatory mediators such as TNF-α in response to an inflammatory stimuli in the airways [27]. Furthermore, a study of 32 healthy volunteers found that salmeterol was able to reduce neutrophil recruitment and degranulation post LPS-inhalation [33]. Our findings extend these observations by demonstrating that LABAs have direct anti-inflammatory effects on COPD airway epithelial cells, which are the primary sites of disease in COPD.

We also extend previous findings by demonstrating that the anti-inflammatory effects in the airways treated with LABAs are mediated by the β2AR. While the exact downstream mechanism for interaction with inflammatory pathways is unclear, we postulate that olodaterol exerts an effect on NF-κB, a transcription factor for many cytokines including IL-8. LPS and RSV trigger an innate inflammatory response via different mechanisms but both lead to activation of NF-κB. In lung epithelial cells, RSV drives production of IL-8 through intracellular activation of Toll-like receptor 3 (via MyD88-independent pathway for later NF-κB activation) and retinoic acid-inducible gene I receptor (involved in translocation of NF-κB) [34]. LPS, meanwhile, is able to induce NF-κB mediated secretion of IL-8 through activation of TLR4 via the MyD88-dependent and MyD88-independent pathways [35]. Olodaterol may therefore play a role in stabilizing the inhibition of cytosolic NF-κB (through IκB proteins) and preventing translocation into the nucleus, leading to an inhibition of cytokine production.

Clinically, patients are prescribed olodaterol at a daily dose of 5 µg aerosolized in 22.1 µL of carrier fluid [36]. The experimental concentration of 10 µM olodaterol was chosen based on calculations of this aerosolized dose of olodaterol into the average patient’s airways’ periciliary fluid volume. The calculation for this concentration was derived from the calculations used by Dorscheid et al. to approximate the concentration of the ICS dexamethasone in the sol layer in one inhalation, assuming 10–30% deposition [37]. The resulting concentration was approximately 10 µM. To test dose-concentration, we evaluated various doses of olodaterol in the primary ALI cultures and observed that 3 µM demonstrated sub-optimal IL-8 suppression and concentrations above 10 µM were associated with notable toxicity to the cells. As the drug concentration used in this study mimics that of in vivo applications, the current study results suggest clinical relevance. It is also notable that the anti-inflammatory effect of 10 µM of olodaterol on LPS-induced IL-8 production in the airway cells is similar to that achieved by 1 µM of dexamethasone on TNF-α induced IL-8 secretion (approximately 50%) [38]. The 1 µM dose of dexamethasone approximates the dissolved concentration of one inhalation of aerosolized dexamethasone observed in the periciliary fluid of the airways [37]. In addition, it is worth noting that there is previously published work detailing the ability of the LABA formoterol in inhibiting coronavirus (HCoV-229E) infection-induced IL-8 secretion in human nasal epithelial cells [39]. Thus, there is precedence for the ability of LABAs to inhibit viral infection-induced inflammation, as was also shown in this paper. Together, the data suggest that LABAs independently exert an anti-inflammatory effect in the airways of COPD patients and may explain their salutary effects on the risk of exacerbation in COPD patients when used alone or in combination with ICS.

There were some limitations to the current study. Firstly, olodaterol appeared to also suppress the extent of RSV infection. Olodaterol may therefore have an effect in inhibiting viral replication or viral entry into the cell but the scope of this paper did not explore these potential effects. Secondly, this project used IL-8 as the biomarker of choice to monitor the anti-inflammatory effects of olodaterol. IL-8 is a known neutrophil chemoattractant and has been implicated in COPD pathogenesis. However, inflammation encompasses a wide variety of cytokines and inflammatory mediators and the effect of olodaterol on these other markers warrants further exploration. For example, it has been demonstrated that the airway epithelium constitutively secretes IL-10 [40], which exhibits a direct modulating effect on inflammation through inhibiting IL-8 gene expression [41]. Recent data from Ağaç et. al. showed that activation of the β2AR can up-regulate IL-10 [42]. Thus, olodaterol may modulate IL-8 suppression through integration with an IL-10 secreting pathway via β2AR. Thirdly, this study focused solely on the anti-inflammatory effects of olodaterol. It would also be worthwhile to explore whether this same effect of olodaterol can be extrapolated to other LABAs (eg. formoterol, salmeterol).


Olodaterol demonstrates significant anti-inflammatory effects on airway epithelial cells in addition to its well-documented bronchodilation effects in the airways of COPD patients. We present evidence of olodaterol’s ability to attenuate IL-8 secretion and decrease mucus production. We also showed that the anti-inflammatory effects of olodaterol are mediated through the β2-adrenergic receptor in the airway epithelium, which is the established binding receptor of olodaterol. These observations may explain the salutary effects of LABAs in reducing exacerbations in COPD patients. More research is required to elucidate the mechanistic pathway behind these observations and whether they are applicable to other LABAs as well as their clinical translation.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.



Air–liquid interface


β2-Adrenergic receptor


Bronchial epithelial cells


Chronic obstructive pulmonary disease


Inhaled corticosteroid




Long-acting beta 2 agonist



MOI1 :

Multiplicity of infection 1


Mucin 5AC


Myeloid differentiation primary response 88


Nuclear factor kappa B


Respiratory syncytial virus


Short-acting beta agonist


Toll-like receptor 4


  1. 1.

    Matsumoto K, Inoue H. Viral infections in asthma and COPD. Respir Investig. 2014;52:92–100.

    PubMed  Article  Google Scholar 

  2. 2.

    Ramadan WH, Kabbara WK, Abilmona RM. Olodaterol for the treatment of chronic obstructive pulmonary disease. Am J Health Syst Pharm. 2016;73:1135–43.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Tse R, Marroquin BA, Dorscheid DR, White SR. Beta-adrenergic agonists inhibit corticosteroid-induced apoptosis of airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2003;285:L393-404.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Foronjy RF, Dabo AJ, Taggart CC, Weldon S, Geraghty P. Respiratory syncytial virus infections enhance cigarette smoke induced COPD in mice. PLoS ONE. 2014;9:e90567.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  6. 6.

    Rezaee F, DeSando SA, Ivanov AI, Chapman TJ, Knowlden SA, Beck LA, Georas SN. Sustained protein kinase D activation mediates respiratory syncytial virus-induced airway barrier disruption. J Virol. 2013;87:11088–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Sikkel MB, Quint JK, Mallia P, Wedzicha JA, Johnston SL. Respiratory syncytial virus persistence in chronic obstructive pulmonary disease. Pediatr Infect Dis J. 2008;27:S63-70.

    PubMed  Article  Google Scholar 

  8. 8.

    Deeks ED. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75:665–73.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJ. 24-hour bronchodilation following a single dose of the novel beta(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666–72.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155:291–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Gibb A, Yang LP. Olodaterol: first global approval. Drugs. 2013;73:1841–6.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Incorvaia C, Montagni M, Makri E, Riario-Sforza GG, Ridolo E. Striving for optimal bronchodilation: focus on olodaterol. Int J Chron Obstruct Pulmon Dis. 2016;11:439–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, Schnapp A. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Borghardt JM, Weber B, Staab A, Kunz C, Kloft C. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. Br J Clin Pharmacol. 2016;82:739–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Bouyssou T, Hoenke C, Rudolf K, Lustenberger P, Pestel S, Sieger P, Lotz R, Heine C, Buttner FH, Schnapp A, Konetzki I. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20:1410–4.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Miravitlles M, D’Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17:112.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  17. 17.

    Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182–91.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Wang J, Nie B, Xiong W, Xu Y. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37:204–11.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    De Rose V, Molloy K, Gohy S, Pilette C, Greene CM. Airway epithelium dysfunction in cystic fibrosis and COPD. Mediat Inflamm. 2018;2018:1309746–1309746.

    Google Scholar 

  20. 20.

    Hegele RG, Robinson PJ, Gonzalez S, Hogg JC. Production of acute bronchiolitis in guinea-pigs by human respiratory syncytial virus. Eur Respir J. 1993;6:1324–31.

    CAS  PubMed  Google Scholar 

  21. 21.

    Kaan PM, Hegele RG. Interaction between respiratory syncytial virus and particulate matter in guinea pig alveolar macrophages. Am J Respir Cell Mol Biol. 2003;28:697–704.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–82.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Toor A, Culibrk L, Singhera GK, Moon K-M, Prudova A, Foster LJ, Moore MM, Dorscheid DR, Tebbutt SJ. Transcriptomic and proteomic host response to Aspergillus fumigatus conidia in an air-liquid interface model of human bronchial epithelium. PLoS ONE. 2018;13:e0209652–e0209652.

    PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Bagdonas E, Raudoniute J, Bruzauskaite I, Aldonyte R. Novel aspects of pathogenesis and regeneration mechanisms in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:995–1013.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Caramori G, Di Gregorio C, Carlstedt I, Casolari P, Guzzinati I, Adcock IM, Barnes PJ, Ciaccia A, Cavallesco G, Chung KF, Papi A. Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease. Histopathology. 2004;45:477–84.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Bosmann M, Grailer JJ, Zhu K, Matthay MA, Sarma JV, Zetoune FS, Ward PA. Anti-inflammatory effects of beta2 adrenergic receptor agonists in experimental acute lung injury. FASEB J. 2012;26:2137–44.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Wex E, Kollak I, Duechs MJ, Naline E, Wollin L, Devillier P. The long-acting beta2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation. Br J Pharmacol. 2015;172:3537–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Keränen T, Hömmö T, Hämäläinen M, Moilanen E, Korhonen R. Anti-inflammatory effects of β2-receptor agonists salbutamol and terbutaline are mediated by MKP-1. PLoS ONE. 2016;11:e0148144.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29.

    Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Group SCOS, Jeffery PK. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006;173:736–43.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Rider CF, Altonsy MO, Mostafa MM, Shah SV, Sasse S, Manson ML, Yan D, Karrman-Mardh C, Miller-Larsson A, Gerber AN, et al. Long-Acting beta2-adrenoceptor agonists enhance glucocorticoid receptor (GR)-mediated transcription by gene-specific mechanisms rather than generic effects via GR. Mol Pharmacol. 2018;94:1031–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Altonsy MO, Mostafa MM, Gerber AN, Newton R. Long-acting beta2-agonists promote glucocorticoid-mediated repression of NF-kappaB by enhancing expression of the feedback regulator TNFAIP3. Am J Physiol Lung Cell Mol Physiol. 2017;312:L358–70.

    PubMed  Article  Google Scholar 

  32. 32.

    Holden NS, George T, Rider CF, Chandrasekhar A, Shah S, Kaur M, Johnson M, Siderovski DP, Leigh R, Giembycz MA, Newton R. Induction of regulator of G-protein signaling 2 expression by long-acting beta2-adrenoceptor agonists and glucocorticoids in human airway epithelial cells. J Pharmacol Exp Ther. 2014;348:12–24.

    PubMed  Article  CAS  Google Scholar 

  33. 33.

    Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM, van der Zee JS, Bresser P, van der Poll T. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med. 2005;172:878–84.

    PubMed  Article  Google Scholar 

  34. 34.

    Kolli D, Velayutham TS, Casola A. Host-viral interactions: role of pattern recognition receptors (PRRs) in human pneumovirus infections. Pathogens. 2013;2:232–63.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  35. 35.

    Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Boehringer Ingelheim. Striverdi Respimat (olodaterol) [package insert] U.S. Food and Drug Administration website. 2018.

  37. 37.

    Dorscheid DR, Wojcik KR, Sun S, Marroquin B, White SR. Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med. 2001;164:1939–47.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Rahman MM, Alkhouri H, Tang F, Che W, Ge Q, Ammit AJ. Sphingosine 1-phosphate induces neutrophil chemoattractant IL-8: repression by steroids. PLoS ONE. 2014;9:e92466.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  39. 39.

    Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, Shimotai Y, Momma H, Ichinose M, Kawase T. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58:155–68.

    PubMed  PubMed Central  Article  Google Scholar 

  40. 40.

    Bonfield T, Konstan M, Burfeind P, Panuska J, Hilliard J, Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995;13:257–61.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Tabary O, Muselet C, Escotte S, Antonicelli F, Hubert D, Dusser D, Jacquot J. Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the I(k)B kinase alpha/beta complex. Am J Pathol. 2003;162:293–302.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Ağaç D, Estrada LD, Maples R, Hooper LV, Farrar JD. The β2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion. Brain Behav Immun. 2018;74:176–85.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

Download references


The authors thank the Pacific Lung Health Centre research coordinators for patient recruitment and consent, and the bronchoscopy team for the collection of the bronchial brushes. We would also like to thank Amrit Samra from the Centre for Heart Lung Innovation for tissue processing.


This work was supported by the Canadian Institutes of Health Research (CIHR, 20R25167), The Michael Smith Foundation for Health Research (MSFHR, NJZY 20R7746), AllerGen-Networks of Excellence (NMJK 20R12545), and the British Columbia Lung Association (NRLQ 20R00475). DS is a Tier 1 Canada Research Chair in COPD and holds the De Lazzari Family Chair at the Centre for Heart Lung Innovation. Boehringer Ingelheim provided funding and olodaterol hydrochloride in support of this study but was not involved in the study design or data analysis. No other funding source had a role in the study design, data collection and analysis, drafting of the manuscript, and decision to submit the article for publication.

Author information




Conception and design of the study was established by DD, DS and NY. JL acquired the patients bronchial samples. Experimental data was acquired by GS, NY, and RY. Data was analyzed by NY and GS. Data was interpreted by all authors. Drafting of the manuscript was accomplished by NY, GS and RY. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Delbert R. Dorscheid.

Ethics declarations

Ethics approval and consent to participate

All experiments in this study were approved by the Research Ethics Board of University of British Columbia/Providence Healthcare (REB# H11-02713 and REB# H15-01778).

Consent for publication

Not applicable.

Competing interests

MP is an employee of Boehringer Ingelheim, which supported this study. DS has received honoraria for speaking engagements from Astrazeneca, Boehringer Ingelheim and Novartis and received research funding from Astrazeneca, Boehringer Ingelheim and Merck. The other authors declare no relevant conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Olodaterol dose response on IL-8 secretion in ALI cultures. Figure S2. Apical treatment of 10 µM olodaterol is non-toxic to ALI cultures. Figure S3. Quantification of B2AR and GAPDH mRNA transcript levels after transfection by siRNA.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yang, N., Singhera, G.K., Yan, Y.X. et al. Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells. Respir Res 22, 65 (2021). https://doi.org/10.1186/s12931-021-01659-2

Download citation


  • Airway epithelium
  • Interleukin-8
  • Airway inflammation
  • Olodaterol
  • Long-acting beta agonist
  • COPD
  • Beta 2-adrenergic receptor